T‐cell adoptive immunotherapy for BK nephropathy in renal transplantation

Sadia Jahan(Royal Adelaide Hospital), George John(Department of Biotechnology), Sweera Rehan(QIMR Berghofer Medical Research Institute), Corey Smith(QIMR Berghofer Medical Research Institute), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Michelle A. Neller(QIMR Berghofer Medical Research Institute), Carla Scuderi(Royal Brisbane and Women's Hospital), Pauline Crooks(QIMR Berghofer Medical Research Institute), Leo Francis(Royal Brisbane and Women's Hospital), George Ambalathingal(The University of Queensland)
Transplant Infectious Disease
July 1, 2020
10.1111/tid.13399
Cited by 22

Related Papers

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.
|Journal of Clinical Pathology|1984|261
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
|Blood|2006|250
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
|Proceedings of the National Academy of Sciences|2004|235
BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies
|Clinical Microbiology Reviews|2017|226